VectivBio reels in $110m

VectivBio AG, a Swiss developer of transformational medicines for patients with serious rare diseases, has raised $110 million in financing.

VectivBio AG, a Swiss developer of transformational medicines for patients with serious rare diseases, has raised $110 million in financing. The investors included Surveyor Capital, Cormorant Capital, Eventide Asset Management, Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.

Source: Press Release